Cardiff Oncology Reports Q2 2026 Results and Business Update

What Happened

• Cardiff Oncology, Inc. (CRDF) filed a Form 8-K on August 11, 2026 (Item 2.02) furnishing a press release that announces a business update and the company's financial results for the quarter ended June 30, 2026. The press release is included as Exhibit 99.1 to the 8-K. The Form 8-K was signed by CEO Mani Mohindru.

Key Details

• Filing date: August 11, 2026.
• Reporting period: Quarter ended June 30, 2026 (Q2 2026).
• Item reported: 2.02 (Results of Operations and Financial Condition); press release furnished as Exhibit 99.1.
• Signature: Form 8-K signed by Mani Mohindru, Chief Executive Officer.

Why It Matters

• Quarterly results and the business update can affect Cardiff Oncology’s stock and investor outlook because they provide the latest information on revenue, expenses, cash position, and operational progress.
• Investors should review the furnished press release (Exhibit 99.1) for the specific financial figures and management commentary to assess company performance and near-term expectations.